Short term suppression of hyperacute renal allograft rejection in presensitised dogs with prostacyclin

Prostaglandins
A R MundyJ R Vane

Abstract

One of the main features of hyperacute renal allograft rejection in presensitised dogs is platelet aggregation within the kidney as detected by light microscopy and renal arterio-venous platelet counts. Graft failure, as determined by reduction and ultimate cessation of renal blood flow and urine production, can be abrogated in the short term by prostacyclin which is the most potent inhibitor of platelet aggregation yet discovered. After 4 h of extracorporeal perfusion, by which time all control kidneys had been rejected, all prostacyclin treated kidneys had normal or above normal blood flow rates, were producing urine and were similar histologically (light microscopy) to 4-hour autografts.

References

May 17, 1979·The New England Journal of Medicine·S Moncada, J R Vane
Feb 2, 1978·Nature·P M BolgerL M Slotkoff
Aug 20, 1970·The New England Journal of Medicine·T E StarzlC G Halgrimson
Jan 2, 1969·The New England Journal of Medicine·G M Williams, F Milgrom

❮ Previous
Next ❯

Citations

Dec 31, 2003·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Johannes WaiserHans-Hellmut Neumayer
May 1, 1983·British Heart Journal·J R Vane
Jan 1, 1984·Pathology, Research and Practice·A T TrieblingA Gabryelewicz
Mar 1, 1983·Stroke; a Journal of Cerebral Circulation·S Moncada
May 1, 1982·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·S Moncada
Apr 1, 1985·Klinische Wochenschrift·M GoerigG Schettler
Aug 29, 1981·Lancet·M L FoeghG E Schreiner

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.